Seiji Wakao, JPMorgan, queried the feasibility of achieving ¥1 trillion in oncology revenue amid Datroway’s setbacks. Ogawa stated that ENHERTU’s performance could potentially fill the gap, with a ...

Hiroyuki Okuzawa, current COO and incoming CEO of Daiichi Sankyo, talks about the pharmaceutical company's product pipeline, including its cancer treatments, and its global partnerships with ...

AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Such payment by Daiichi Sankyo satisfies all potential clinical, regulatory and sales milestone payments, as well as royalties of products that ... lung cancer in the European Union.

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines for approval at its ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer ...

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...